Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III daraxonrasib versus docetaxel in previously treated RAS-mutant non-small cell lung cancer
ISRCTN17936325Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- May 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of daraxonrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-free survival and Overall survival. Started May 2025; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN17936325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17936325.